Sintx Technologies (NASDAQ:SINT) (NASDAQ: SINT) is a specialty medical device company that develops and manufactures advanced biomaterial solutions for orthopedic and reconstructive surgery. Founded in 2002 and headquartered in Ann Arbor, Michigan, Sintx has pioneered porous silicon-based and glass-derived substrate technologies designed to enhance bone healing and implant integration. The company serves a diverse customer base that includes distributors, original equipment manufacturers (OEMs) and healthcare institutions across North America, Europe and select Asian markets.
The core of Sintx’s product portfolio is its proprietary PorousSi™ platform, which features three-dimensional, interconnected pore structures intended to support cellular in-growth and vascularization. These biomaterials are used as coatings and standalone implants for spinal fusion, trauma fixation, cranio-maxillofacial reconstruction and sports medicine procedures. Sintx also offers customized device components made from medical-grade borosilicate glass and silicon-based ceramics, enabling partners to enhance existing implant designs or develop next-generation therapies.
Sintx maintains manufacturing and research operations in the United States, adhering to ISO 13485 standards and holding multiple FDA clearances for its implantable materials and devices. The company collaborates with leading academic and clinical institutions to validate performance in preclinical and clinical settings, while investing in process improvements to scale production and meet evolving regulatory requirements. Sintx’s integrated approach combines material science expertise with engineering capabilities to deliver reproducible, high-quality products.
Under the leadership of an experienced executive team, Sintx Technologies continues to focus on innovation, strategic partnerships and geographic expansion. The company’s management brings together seasoned professionals in medical device development, regulatory affairs and manufacturing operations. Looking ahead, Sintx aims to broaden its product offerings, pursue additional regulatory clearances and strengthen its position as a key supplier of advanced biomaterial solutions in the global orthopedic market.
